National guideline for the management of prostatitis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases).
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D002908:Chronic Disease; D002939:Ciprofloxacin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D015242:Ofloxacin / Q000627:therapeutic use; D011472:Prostatitis / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D014552:Urinary Tract Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology
D000317:Adrenergic alpha-Antagonists; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000892:Anti-Infective Agents, Urinary; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002511:Cephalosporins; D002939:Ciprofloxacin; D015242:Ofloxacin